Arrowhead Research Corp (ARWR) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $15. Cantor Fitzgerald advised their investors in a research report released on Aug 18, 2016.
On the company’s financial health, Arrowhead Research Corp reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36. The company had revenue of $39.58 million for the quarter, compared to analysts expectations of $.05 million. The company’s revenue was down -68.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.27 EPS.
Arrowhead Research Corp opened for trading at $6.14 and hit $6.35 on the upside on Wednesday, eventually ending the session at $6.34, with a gain of 2.76% or 0.17 points. The heightened volatility saw the trading volume jump to 5,77,219 shares. Company has a market cap of $385 M.
In a different news, on Jan 4, 2016, Kenneth Allen Myszkowski (Chief Financial Officer) sold 23,347 shares at $6.13 per share price. According to the SEC, on Jan 14, 2015, Mauro Ferrari (director) purchased 2,300 shares at $6.90 per share price. On Jan 7, 2015, David L. Lewis (Chief Scientific Officer) sold 15,000 shares at $8.01 per share price, according to the Form-4 filing with the securities and exchange commission.
Arrowhead Research Corporation is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. The Company’s products include ARC-520 ARC-521 ARC-AAT ARC-F12 ARC-HIF2 and ARC-LPA. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog-containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 with the goal of providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.